Onyx Biotec Limited (NSE:ONYX)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Manufacturing of Pharmaceutical Products	694.69M	619.51M	537.49M	394.92M	448.61M
Manufacturing of Pharmaceutical Products Growth	12.14%	15.26%	36.10%	-11.97%	-
Total	694.69M	619.51M	537.49M	394.92M	448.61M
Total Growth	12.14%	15.26%	36.10%	-11.97%	-

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
India	694.69M	619.51M	537.49M	394.92M	448.61M
India Growth	12.14%	15.26%	36.10%	-11.97%	-
Total	694.69M	619.51M	537.49M	394.92M	448.61M
Total Growth	12.14%	15.26%	36.10%	-11.97%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 6, 2026

Data Sources Report a data error